Clinical Characteristics and Long-term Prognosis Analysis of Patients with Primary Bone Lymphoma

OBJECTIVE: To analyze the clinical characteristics and long-term prognosis of patients with primary bone lymphoma (PBL).

METHODS: The clinical data of 21 patients with PBL treated in our center from 2005 to 2018 were analyzed retrospectively, the clinical characteristics and the factors affecting prognosis of the patients were analyzed.

RESULTS: The median age of all the 21 newly diagnosed PBL patients was 40(12-71) years old. Ostealgia was the initial symptom in most of the patients (19/21,90.5%). 42.9%(9/21) of the patients showed single bone lesion only. 571% (12/21) of the patients showed diffuse large B cell lymphoma. 28.6% (6/21) of the patients showed anaplastic large cell lymphoma and 9.5% (2/21) of the patients showed T cell lymphoblastic lymphoma. All the patients received chemotherapy (CHOP or CHOP like regimen, 33.3% plus rituximab) with or without radiotherapy and/or autologous hematopoietic stem cell transplantation (ASCT). 18 patients achieved clinical remission (including 15 for CR and 3 for PR). The median follow-up time was 48 months. The 5-year overall survival rate and progression-free survival rate of the patients were was 67.5% and 63.7%, respectively. The single factors analysis showed that ASCT was the important prognostic factor of PFS, while the single or multiple bone lesion was the factors affecting OS of the patients. There were no statistical differences with the effects of age, sex, stage, ECOG score, LDH level, B symptoms and radiotherapy for the prognosis of patients.

CONCLUSION: Diffuse large B cell lymphoma is the most common pathological type of PBL. Chemotherapy is the main treatment, which can be combined with radiotherapy and/or ASCT. The ASCT and the number of bone lesion are the factors for long time survival of the patients.

Medienart:

E-Artikel

Erscheinungsjahr:

2022

Erschienen:

2022

Enthalten in:

Zur Gesamtaufnahme - volume:30

Enthalten in:

Zhongguo shi yan xue ye xue za zhi - 30(2022), 1 vom: 05. Feb., Seite 126-130

Sprache:

Chinesisch

Beteiligte Personen:

Zhong, Kai-Li [VerfasserIn]
Cao, Bao-Ping [VerfasserIn]
Guo, Xiao-Chuan [VerfasserIn]
Huang, Le-Fu [VerfasserIn]
Wang, Wei-Xia [VerfasserIn]
Wang, Bin [VerfasserIn]
Zhang, Wei-Jing [VerfasserIn]

Links:

Volltext

Themen:

4F4X42SYQ6
5J49Q6B70F
80168379AG
8N3DW7272P
Clinical characteristic
Cyclophosphamide
Doxorubicin
Journal Article
Lymphoma
Prednisone
Primary bone lymphoma
Prognosis
Rituximab
VB0R961HZT
Vincristine

Anmerkungen:

Date Completed 08.02.2022

Date Revised 31.05.2022

published: Print

Citation Status MEDLINE

doi:

10.19746/j.cnki.issn.1009-2137.2022.01.020

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM336561466